Weight-loss medication should be treated with caution.
Dr Jeni Worden last medically reviewed this article in February 2010.
Weight-loss medication should be treated with caution.
Dr Jeni Worden last medically reviewed this article in February 2010.
In the long term, very few people benefit from slimming pills (or anti-obesity medication as they're more formally called). They should be viewed generally as a last resort, to help people who are grossly overweight, have already lost some weight and are now struggling to lose more.
Problems with slimming pills in the past have left doctors very guarded about their use. Amphetamine-type slimming pills were popular 30 to 40 years ago, but it took some time for doctors to realise they can be addictive and harmful. Despite these problems, they were still widely handed out, often by poorly trained medical staff. Few people managed to diet successfully with them and, more importantly, keep weight off and many became physically hooked or addicted to them.
Many slimming pills, including more recent and supposedly safer types of appetite-suppressant amphetamine drugs, such as dexfenfluramine, have now been taken off the market because of potential side effects and complications, such as heart disease.
However, as obesity is such a current concern, there's a huge effort going into developing effective and safe medicines to help people lose weight and in recent years some of the products of this research have come into use.
Current anti-obesity drugs can be broadly divided into three categories:
Other anti-obesity drugs are currently in development and may come into general use in the next few years.
The Royal College of Physicians (RCP) advises doctors to only prescribe anti-obesity drugs in special circumstances. For example, as part of an overall treatment plan for the management of obesity for people aged 18 to 65 years with a body mass index (BMI) of 30 or more. Or where someone has a BMI of 27 or more and has another significant disease, such as type 2 diabetes or high cholesterol. The person must have already made serious attempts to lose weight by dieting, exercise and/or other changes in their behaviour but failed to lose ten per cent of their weight after at least three months.
It's important to be aware that not everyone responds to drug therapy, and most doctors recommend that weight loss should be measured after 12 weeks and the anti-obesity drugs stopped if someone has not achieved a five per cent weight reduction. And, like any treatment, they have side effects. Sibutramine sometimes increases blood pressure and can cause a potentially fatal lung complication, for example, while Orlistat can cause diarrhoea and flatulence.
In general, the idea that overweight people have a slow metabolism is a complete myth. The heavier you are the harder your body has to work to carry the weight and the greater your metabolic rate. The only exceptions are people with conditions such as a clinically under-active thyroid gland, who are generally ill with other symptoms too.
By far the healthiest and most effective way to control your weight is through long-term healthy eating and regular exercise (you will need to do at least 150 minutes a week of seriously-out-of-puff exercise, ideally broken down into daily chunks) supported by counselling and behaviour modification, which you should find at a slimming club.
All content within BBC Health is provided for general information only, and should not be treated as a substitute for the medical advice of your own doctor or any other health care professional. The BBC is not responsible or liable for any diagnosis made by a user based on the content of the BBC Health website. The BBC is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites. See our Links Policy for more information. Always consult your own GP if you're in any way concerned about your health.
BBC © 2012 The BBC is not responsible for the content of external sites. Read more.
This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.